Class Action Lawsuit Against Capricor Therapeutics
Investors who acquired securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) during a specified period have been alerted to a class action lawsuit. The legal action is primarily led by Levi & Korsinsky, LLP, who has issued a notification regarding the commencement of a complaint that seeks to recover losses sustained by shareholders. This lawsuit emphasizes the importance of transparency and accurate information in the securities market.
Details of the Lawsuit
The class action lawsuit, known as Hau Xiang Leong v. Capricor Therapeutics, Inc., et al., was filed in the United States District Court for the Southern District of California. It focuses on the timeline between October 9, 2024, and July 10, 2025, during which Capricor was accused of misleading investors regarding its lead cell therapy candidate drug, deramiocel. This drug was being evaluated for its potential effectiveness in treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Investor Information
The lawsuit is significant because it allows affected investors to seek legal recourse for their losses. Individuals who purchased Capricor securities during the designated timeframe are encouraged to consider their options. Importantly, participation in the lawsuit does not require an individual to be named as the lead plaintiff, which lowers the barrier for many shareholders looking to get involved.
Financial Implications
Since the announcement of the class action, the stock price of Capricor has seen a significant decline. Following the issuance of a damaging Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), which indicated that Capricor's Biologics License Application did not meet essential requirements, the share price plummeted from $11.40 on July 10, 2025, to $7.64 by July 11, 2025. This sharp decline illustrates the volatility surrounding pharmaceutical stocks, especially those under regulatory scrutiny.
Performance of Capricor Therapeutics
Capricor has faced challenges in its pursuit of regulatory approval for deramiocel. While the initial enthusiasm from investors was palpable, as evidenced by the high stock price prior to the FDA's response, the subsequent events have led to a reassessment of the company’s prospects. Investors are encouraged to remain informed about Capricor’s forthcoming actions and their implications.
Why Choose Levi & Korsinsky?
With a strong history of advocacy for shareholders, Levi & Korsinsky has established itself as a prominent firm in securities litigation. Over the past two decades, the firm has recovered hundreds of millions for investors, demonstrating a commitment to holding corporations accountable. Their experience and resources provide affected shareholders with a robust support system as they navigate the complexities of the legal process.
Contact Information
Those interested in learning more about the lawsuit or who want to see if they qualify for inclusion are encouraged to reach out to Levi & Korsinsky directly. Joseph E. Levi, Esq., can be contacted via email at jlevi@levikorsinsky.com or by phone at (212) 363-7500. The firm assures potential clients that there are no costs or obligations associated with the initial consultation.
Frequently Asked Questions
What is the lawsuit about?
The lawsuit is aimed at recovering losses for investors who purchased Capricor Therapeutics stock between October 9, 2024, and July 10, 2025, after being misled about the company’s drug candidate.
How did Capricor's stock react to the news?
Following the announcement of the class action and the FDA's response, Capricor's stock price dropped from $11.40 to $7.64 in just one day.
Do I need to be a lead plaintiff to participate?
No, you do not need to be a lead plaintiff to participate in the claims for recovery.
What makes Levi & Korsinsky a good choice for this lawsuit?
They have a proven track record of success in securities litigation, with significant recoveries for shareholders over the past 20 years.
How can I contact Levi & Korsinsky?
You can contact Joseph E. Levi via email at jlevi@levikorsinsky.com or by phone at (212) 363-7500.
